Chronology

Published Sep 4, 2026

Updated Sep 4, 2026

---

Collaboration with NVIDIA to accelerate the development of AI capabilities. Mar 2025.

CE mark. April 2023.

FDA clearance. Dec 2022.

First-in-human experience (Guy-Bernard Cadière, CHU Saint-Pierre in Brussels). Dec 2022.

$31.3 million in Series A funding from GT Healthcare Capital&Partners and J&J Innovation. 2022.

First integrated prototype (Apollo 12). Sep 2021.

strategic partnership with King’s College London. 2021.

MastOR founded (Paris). 2020.

Introduction

Maestro™ is a robotic surgical assistant developed by Moon Surgical, a French-American medical technology company founded in Paris in 2020. Unlike conventional robotic surgery platforms such as the da Vinci, Maestro is designed to assist rather than replace the surgeon.

The surgeon remains at the operating table and performs the procedure using conventional laparoscopic techniques, while Maestro provides robotic assistance with instrument positioning, tissue retraction and endoscope control.

This places Maestro in a different category from traditional master–slave robotic surgery systems.

The Company

Moon Surgical was originally founded as MastOR in Paris by Professor Brice Gayet. In June 2020, the company became a Sofinnova MD Start portfolio company, with Anne Osdoit joining as CEO. The company subsequently developed its Maestro laparoscopic assistance platform.

Moon Surgical combines French and US operations and is headquartered in Paris, with a US office in San Carlos, California.

Maestro

Maestro is a two-arm robotic surgical assistant designed for minimally invasive surgery.

Rather than operating through a surgeon’s console, the system works directly alongside the surgeon at the operating table. Its robotic arms can hold and position laparoscopic instruments and the endoscope, providing stable retraction and visualization while freeing the surgeon’s hands for other tasks.

A key feature is its compatibility with standard laparoscopic instruments, rather than requiring a completely proprietary instrument ecosystem. The system therefore aims to combine some of the advantages of robotic assistance with the familiarity, flexibility and relatively low infrastructure requirements of conventional laparoscopy.

ScoPilot™

An important evolution of Maestro is ScoPilot™, an AI-enabled intraoperative capability designed to assist with laparoscopic visualization. ScoPilot can automatically control the laparoscope based on the surgical field and instrument position, reducing the need for a dedicated camera operator.

This is an important direction for the platform: the robot is moving from simply providing mechanical assistance towards AI-enabled surgical assistance.

Indications and regulatory status

Maestro is primarily intended for minimally invasive soft-tissue surgery, with applications including general surgery and, more recently, gynecological surgery. The platform has been used for procedures including laparoscopic cholecystectomy and other minimally invasive abdominal procedures.

The first version of Maestro received FDA 510(k) clearance in December 2022 following its first-in-human clinical program. The first version received CE Mark in April 2023. The commercial version subsequently received a second FDA clearance on June 3, 2024. The FDA classified this version as an operating-room powered device.

Further FDA clearances followed as the platform evolved. In March 2025, the FDA cleared Maestro as a software-controlled endoscope and instrument holder, and in June 2025 another 510(k) clearance expanded the system’s regulatory footprint.

Prior to commencing my venture into robotic surgery, I had established a firm grounding as an oncologic surgeon. My experience encompassed a wide range of resection and reconstructive procedures, as well as proficiency in minimally invasive surgical techniques and endoscopic surgery. These acquired skills and expertise serve as fundamental pillars for achieving success in robotic surgery.

---

Disclaimer and Accuracy Statement

All medical information provided on headneckroboticsurgery.com is uploaded and reviewed by a qualified medical doctor with the utmost care and in good faith. The content is accurate, up-to-date, and intended to offer valuable insights for both health professionals and patients. Specific update dates are noted to ensure transparency and relevance.

If you come across any information that you believe to be inaccurate or outdated, please do not hesitate to contact us directly. We are committed to maintaining the highest standards of accuracy and promptly addressing any concerns.